Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:ADAG NASDAQ:CLYM NASDAQ:RLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.32-1.1%$4.39$1.34▼$5.15$610.33M0.761.06 million shs1.11 million shsADAGAdagene$3.57-0.3%$3.71$1.30▼$4.75$169.64M0.59172,222 shs250,190 shsCLYMClimb Bio$11.44+4.9%$9.96$1.16▼$12.48$624.74M0.091.09 million shs858,934 shsRLMDRelmada Therapeutics$6.65+2.0%$7.03$0.52▼$8.00$683.88M0.391.06 million shs1.13 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-1.14%-0.92%-15.13%+22.03%+175.16%ADAGAdagene-0.28%+7.53%-3.51%-13.56%+80.30%CLYMClimb Bio+4.86%+8.44%+0.26%+62.73%+807.94%RLMDRelmada Therapeutics+1.99%+11.76%-11.21%+12.52%+767.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.32-1.1%$4.39$1.34▼$5.15$610.33M0.761.06 million shs1.11 million shsADAGAdagene$3.57-0.3%$3.71$1.30▼$4.75$169.64M0.59172,222 shs250,190 shsCLYMClimb Bio$11.44+4.9%$9.96$1.16▼$12.48$624.74M0.091.09 million shs858,934 shsRLMDRelmada Therapeutics$6.65+2.0%$7.03$0.52▼$8.00$683.88M0.391.06 million shs1.13 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-1.14%-0.92%-15.13%+22.03%+175.16%ADAGAdagene-0.28%+7.53%-3.51%-13.56%+80.30%CLYMClimb Bio+4.86%+8.44%+0.26%+62.73%+807.94%RLMDRelmada Therapeutics+1.99%+11.76%-11.21%+12.52%+767.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$11.50166.20% UpsideADAGAdagene 3.00Buy$8.00124.09% UpsideCLYMClimb Bio 3.07Buy$21.7389.92% UpsideRLMDRelmada Therapeutics 2.71Moderate Buy$12.0080.45% UpsideCurrent Analyst Ratings BreakdownLatest ADAG, CLYM, ACRS, and RLMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026CLYMClimb Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$17.006/11/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $20.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.006/2/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$13.006/1/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/12/2026CLYMClimb Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.005/8/2026CLYMClimb Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$15.00 ➝ $17.005/6/2026CLYMClimb Bio Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$21.005/6/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $19.00(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$7.83M77.05N/AN/A$0.85 per share5.08ADAGAdagene$7.67M22.06N/AN/A$0.75 per share4.76CLYMClimb BioN/AN/AN/AN/A$3.36 per shareN/ARLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)ADAGAdagene-$17.61MN/AN/AN/AN/AN/AN/AN/AN/ACLYMClimb Bio-$59.85M-$0.78N/AN/AN/AN/A-31.45%-30.39%8/11/2026 (Estimated)RLMDRelmada Therapeutics-$57.38M-$1.09N/AN/AN/AN/A-71.22%-64.46%8/6/2026 (Estimated)Latest ADAG, CLYM, ACRS, and RLMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026RLMDRelmada Therapeutics-$0.18-$0.22-$0.04-$0.22N/AN/A5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million5/7/2026Q1 2026CLYMClimb Bio-$0.26-$0.20+$0.06-$0.20N/AN/A4/1/2026Q4 2025ADAGAdagene-$0.28-$0.0440+$0.2360-$0.0440$17.50 million$3.84 million3/19/2026Q4 2025RLMDRelmada Therapeutics-$0.14-$0.27-$0.13-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AADAGAdageneN/AN/AN/AN/AN/ACLYMClimb BioN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03ADAGAdagene0.033.073.07CLYMClimb BioN/A27.8627.86RLMDRelmada TherapeuticsN/A18.2518.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%ADAGAdagene9.51%CLYMClimb Bio69.76%RLMDRelmada Therapeutics45.24%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics4.80%ADAGAdagene21.20%CLYMClimb Bio2.60%RLMDRelmada Therapeutics14.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million132.96 millionOptionableADAGAdagene26047.39 million37.34 millionNot OptionableCLYMClimb Bio957.26 million55.77 millionN/ARLMDRelmada Therapeutics10104.89 million89.68 millionOptionableADAG, CLYM, ACRS, and RLMD HeadlinesRecent News About These CompaniesRelmada Therapeutics IncJune 12 at 8:23 AM | edition.cnn.comRelmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone ProgramJune 11 at 7:00 AM | globenewswire.comRelmada Therapeutics Increases Authorized Shares After Shareholder VoteMay 28, 2026 | tipranks.comRelmada Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comRelmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights: Strong Financial Position and ...May 13, 2026 | finance.yahoo.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2026 Earnings Call TranscriptMay 13, 2026 | insidermonkey.comRelmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comRelmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comRelmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026May 6, 2026 | globenewswire.comRelmada Therapeutics to Present NDV-01 Abstracts at AUA2026May 5, 2026 | globenewswire.comMizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)April 16, 2026 | theglobeandmail.comDoes Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?April 13, 2026 | zacks.com5 Small Drug Stocks to Buy as Sector Recovery Gains StrengthApril 2, 2026 | zacks.comRelmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And SeeMarch 30, 2026 | seekingalpha.comWall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should KnowMarch 26, 2026 | zacks.comHere’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) StockMarch 25, 2026 | msn.comRelmada wins bullish view at Piper Sandler on cancer therapyMarch 24, 2026 | seekingalpha.comPiper Sandler initiates coverage of Relmada Therapeutics (RLMD) with overweight recommendationMarch 24, 2026 | msn.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 earnings call transcriptMarch 20, 2026 | msn.comRelmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Highlights: Strategic Advancements and ...March 20, 2026 | sg.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADAG, CLYM, ACRS, and RLMD Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$4.32 -0.05 (-1.14%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$4.32 +0.00 (+0.12%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Adagene NASDAQ:ADAG$3.57 -0.01 (-0.28%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$3.58 +0.01 (+0.14%) As of 06/12/2026 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.Climb Bio NASDAQ:CLYM$11.44 +0.53 (+4.86%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$11.35 -0.09 (-0.79%) As of 06/12/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Relmada Therapeutics NASDAQ:RLMD$6.65 +0.13 (+1.99%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$6.60 -0.04 (-0.68%) As of 06/12/2026 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
